Zymeworks (ZYME) Change in Receivables (2021 - 2026)
Zymeworks (ZYME) posted Change in Receivables of $36000.0 for Q1 2026, up 100.15% sequentially from -$24.7 million in Q4 2025, and up 100.12% YoY from $17989.6 in Q1 2025.
Analysis
Zymeworks (ZYME) Change in Receivables (2021 - 2026) Analysis & Trends
Zymeworks has reported Change in Receivables for 6 years, with the latest figure at $36000.0 in Q1 2026.
- Quarterly Change in Receivables rose 100.12% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.9 million (down 215.19% YoY) and the FY2025 annual result came in at -$51.2 million, down 240.82% from the prior year.
- Change in Receivables advanced to $36000.0 in Q1 2026 per ZYME's latest filing, from -$24.7 million in the prior quarter.
- Over five years, Change in Receivables peaked at $33.5 million in Q1 2023 and troughed at -$47.8 million in Q4 2023.
- A 5-year average of -$659882.4 and a median of $36000.0 in 2026 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 697.92% in 2023, down 11886.09% in 2023.
- Over 5 years, Change in Receivables stood at $26.7 million in 2022, then slumped by 279.2% to -$47.8 million in 2023, then soared by 166.18% to $31.6 million in 2024, then plunged by 178.13% to -$24.7 million in 2025, then soared by 100.15% to $36000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $36000.0, -$24.7 million, and $26.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 1.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Mn |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | -24.71 Mn |
| Sep 30, 2025 | 26.72 Mn |
| Jun 30, 2025 | -21.99 Mn |
| Mar 31, 2025 | -31.22 Mn |
| Dec 31, 2024 | 31.63 Mn |
| Sep 30, 2024 | -7.88 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | -47.80 Mn |
| Sep 30, 2023 | 18.46 Mn |
| Jun 30, 2023 | -18.10 Mn |
| Mar 31, 2023 | 33.52 Mn |
| Dec 31, 2022 | 26.67 Mn |
| Sep 30, 2022 | 2.31 Mn |
| Jun 30, 2022 | -151,000.00 |
| Mar 31, 2022 | -11.33 Mn |
| Dec 31, 2021 | 10.69 Mn |